Press coverage about Teva Pharmaceutical Industries (NYSE:TEVA) has been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.3681328425914 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- What Are Analysts Report About Teva Pharmaceutical Industries Limited (TEVA) (nismagazine.com)
- Teva Stock Has Risen Significantly since November Lows: What’s Next? (finance.yahoo.com)
- Teva Pharm directors cut their salaries in half: board member (finance.yahoo.com)
- Mylan’s Valuation in January 2018 (finance.yahoo.com)
- Mylan’s Quarterly Revenue Trend (finance.yahoo.com)
Several equities research analysts recently issued reports on TEVA shares. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Tuesday, December 5th. Evercore ISI set a $38.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Cantor Fitzgerald set a $17.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday, October 26th. Morgan Stanley set a $15.00 price target on shares of Teva Pharmaceutical Industries and gave the company an “underweight” rating in a research report on Thursday, October 5th. Finally, Mizuho reiterated a “hold” rating and set a $15.00 price target on shares of Teva Pharmaceutical Industries in a research report on Monday, October 30th. Seven investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $21.42.
The company also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were paid a $0.085 dividend. The ex-dividend date of this dividend was Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a yield of 1.70%. Teva Pharmaceutical Industries’s dividend payout ratio is currently -12.27%.
ILLEGAL ACTIVITY WARNING: “Teva Pharmaceutical Industries (TEVA) Receiving Somewhat Favorable News Coverage, Report Shows” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/11/teva-pharmaceutical-industries-teva-receiving-somewhat-favorable-news-coverage-report-shows.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.